Skip to main content
. 2021 Feb 1;28(1):357–371. doi: 10.1080/10717544.2021.1879315

Figure 3.

Figure 3.

Tissue plasminogen activator-porous magnetic microrods (tPA-MR) for targeted thrombolytic therapy. (A) Illustration of a new strategy for targeted thrombolytic therapy by tPA-MR with a rotational magnetic field using a mouse model. (B)–(E) The tPA-MRs-mediated thrombolysis effect in a mouse model. (B) The representative images of thrombolysis in a distal middle cerebral artery occlusion (dMCAO) mouse, treated with normal saline. (C) With the treatment of tPA (10 mg/kg), the blood clot was lysed 85 min after injection. (D) The representative images of thrombolysis in the dMCAO mouse treated with MRs (1 mg/kg) under a 5 rotational magnetic field (RMF, 20 Hz, 40 mT). (E) In the tPA-MRs-treated (1 mg/kg) group, thrombus could be lysed in 25 min under a rotational magnetic field (RMF, 20 Hz, 40 mT). (F)-(G) The lysis time for recanalization is significantly shortened with tPA-MRs. Adapted with permission from Ref. (Hu et al., 2018). Copyright 2018 American Chemical Society.